Affinity Asset Advisors LLC Sells 125,000 Shares of Rezolute, Inc. (NASDAQ:RZLT)

Affinity Asset Advisors LLC lessened its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT) by 7.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,575,000 shares of the company’s stock after selling 125,000 shares during the quarter. Rezolute makes up 1.0% of Affinity Asset Advisors LLC’s portfolio, making the stock its 27th biggest position. Affinity Asset Advisors LLC owned 2.72% of Rezolute worth $7,718,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in RZLT. JPMorgan Chase & Co. purchased a new position in shares of Rezolute during the third quarter valued at about $42,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Rezolute by 65.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock worth $112,000 after acquiring an additional 9,000 shares during the period. Virtu Financial LLC lifted its stake in shares of Rezolute by 58.0% in the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock valued at $126,000 after purchasing an additional 9,551 shares during the period. MML Investors Services LLC purchased a new stake in Rezolute in the third quarter worth $57,000. Finally, State Street Corp raised its holdings in Rezolute by 11.6% in the third quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after purchasing an additional 13,000 shares in the last quarter. Institutional investors own 82.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on RZLT. Guggenheim reissued a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. JMP Securities boosted their price objective on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Thursday, February 13th. Finally, Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $24.38.

Rezolute Price Performance

RZLT stock opened at $2.57 on Tuesday. The business has a 50 day simple moving average of $3.65 and a two-hundred day simple moving average of $4.54. Rezolute, Inc. has a 1-year low of $2.22 and a 1-year high of $6.19. The company has a market capitalization of $155.57 million, a price-to-earnings ratio of -2.11 and a beta of 0.97.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. Sell-side analysts anticipate that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Insider Activity

In other news, Director Wladimir Hogenhuis bought 10,000 shares of Rezolute stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average price of $4.70 per share, with a total value of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares in the company, valued at $363,154.90. The trade was a 14.87 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Nevan C. Elam purchased 12,302 shares of the business’s stock in a transaction that occurred on Thursday, March 27th. The shares were purchased at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the acquisition, the chief executive officer now directly owns 224,119 shares in the company, valued at $638,739.15. The trade was a 5.81 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 39,060 shares of company stock worth $130,694. 18.39% of the stock is currently owned by corporate insiders.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.